<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03391856</url>
  </required_header>
  <id_info>
    <org_study_id>2017PHB220</org_study_id>
    <nct_id>NCT03391856</nct_id>
  </id_info>
  <brief_title>Prolonged Isolated Thrombocytopenia After Allo-SCT : N-acetyl-L-cysteine (NAC) Versus Supportive Therapy</brief_title>
  <official_title>A Prospective Randomized Controlled Study for Intervention of Prolonged Isolated Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation: N-acetyl-L-cysteine (NAC) Versus Supportive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Isolated prolonged thrombocytopenia (PT) is a common complication after allogeneic stem cell
      transplantation with significant poor prognosis. No standard treatment is available. The
      current study assigned PT randomly to 2 arms: intervention arm with N-acetyl-L-cysteine (NAC)
      and control arm with supportive therapy.This is a prospective randomized controlled study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. patients diagnosed with PT at day 60 post transplant will be randomized assigned to
           intervention arm (NAC) or controlled arm (supportive therapy: prophylactic platelet
           transfusion was given when platelet count &lt;20000/ul.)

        2. Response will be evaluated at day 90. Response was defined as platelet recovery to &gt;=
           20000/ul for 7 consecutive days without transfusion support during the enrollment
           period. All the other patients not achieved above criteria was defined as no response.

        3. For those without response in both arms, patients will received NAC plus recombinant
           human thrombopoietin (rhTPO) for an additional 30 days. rhTPO was given at 300IU/kg/d
           for 28 consecutive days or platelet &gt; 50000/ul independent of platelet transfusion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>30 days after the start of enrollement</time_frame>
    <description>rate of response after 30 days of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>the day of last follow-up</time_frame>
    <description>survival proportion at the last followup after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-relapse mortality</measure>
    <time_frame>the day of last follow-up</time_frame>
    <description>non-relapse mortality at the last followup after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>grade 2-4 acute graft versus host disease</measure>
    <time_frame>day 100 after transplant</time_frame>
    <description>grade 2-4 aGVHD at day 100 after transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic graft versus host disease</measure>
    <time_frame>the day of last follow-up</time_frame>
    <description>chronic graft versus host disease at the day of last follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Thrombocytopenia</condition>
  <condition>Stem Cell Transplant Complications</condition>
  <arm_group>
    <arm_group_label>intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NAC 400mg p.o tid from day 60 to day 90 post transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controlled arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Supportive therapy including platelet infusion:prophylactic platelet transfusion was given when platelet count &lt;20000/ul</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl-L-cysteine (NAC)</intervention_name>
    <description>NAC treatment for PT: 400mg p.o tid from day 60 to 90 post transplant</description>
    <arm_group_label>intervention arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>supportive therapy</intervention_name>
    <description>prophylactic platelet transfusion was given when platelet count &lt;20000/ul</description>
    <arm_group_label>controlled arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age&gt;= 14 years

          -  diagnosed as PT (defined as platelet count in peripheral blood never achieve
             20000/miro-liter for 7 consecutive days without transfusion at day 60 post
             transplantation)

          -  serum creatine level &lt; ULN (upper limit of normal), serum ALT/AST /TBil&lt;=2 ULN

          -  without active CMV/EBV/ADV reactivation, active GVHD, without relapse or minimal
             residual disease at enrollment

        Exclusion Criteria:

          -  history of asthma

          -  allergy to NAC

          -  refuse to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao-Jun Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peiking University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu-Qian Sun, MD</last_name>
    <phone>86-10-88324577</phone>
    <email>sunyuqian83@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuqian Sun, M.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2018</study_first_submitted>
  <study_first_submitted_qc>January 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2018</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiaojun Huang</investigator_full_name>
    <investigator_title>Head of Peking University Institute of Hematology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

